BTIG Maintains Buy on Humacyte, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Humacyte (NASDAQ:HUMA) and raises the price target from $8 to $11.
July 15, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on Humacyte and raises the price target from $8 to $11, indicating strong confidence in the company's future performance.
The raised price target from $8 to $11 by a reputable analyst suggests increased confidence in Humacyte's future performance, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100